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A Ab bs st tr ra ac ct t    This study aimed to evaluate the plasma homocysteine (tHcy) and folate levels as 
well as the methylenetetrahydrofolate reductase (MTHFR) C677T mutation in 
Egyptian subjects.  Fasting total homocysteine (tHcy) and the (MTHFR) C677T 
mutation were evaluated in 50 healthy young control males (age 35-50 years, Gp1), 
50 elderly males age ranged between 50-75 years without any cardiovascular diseases 
(Gp2) and 50 age matched elderly male patients (Gp3) with myocardial infarction. 
There was a significant elevation of plasma tHcy in the patients group and Gp2 
compared to the young control group (Gp1). The total plasma homocysteine (tHcy) in 
the control group, Gp2 and the patients group were 17.99 ± 9.76, 39.9 ± 20.06 and 
43.8 ± 13.13 µmol/L respectively. The frequency of the TT genotype was 12% in the 
patient group compared with 8 % in the young healthy controls and elderly subjects 
(Gp2). The CT genotype constituted 36%, 48% and 44% in the control group, Gp2 
and the patients group respectively. There was no significant difference in the 
occurrence of the TT genotype between the studied groups. Plasma tHcy correlated 
positively with age, total cholesterol, urea, creatinine, glucose levels and carotid 
intimal thickness (CIT). Conclusion: The MTHFR mutation does not seem to be 
associated with either high tHcy or the occurrence of cardiovascular diseases in the 
studied patients. However, elevated plasma tHcy level positively correlates with age 
in the studied subjects. 
K Ke ey y   w wo or rd ds s    Homocysteine, MTHFR, coronary heart disease 
A Au ut th ho or r   
b bi io og gr ra ap ph hy y   
Mohamed EL-SAMMAK obtained MSc (1998) and Ph.D (2001) in Clinical Laboratory 
Sciences from Nottingham University, UK, and MRCPath (2003) from  Royal College UK. 
He currently works as a lecturer & honorary Consultant in Clinical Pathology at Alexandria 
University, Egypt.  He is involved in several  research projects such as the evaluation of 
methylenetetrahdrofolate reductase gene mutation in Egyptian patients with coronary heart 
disease; evaluation of the clinical utility of procalcitonin in tonsilopharingitis of various 
etiologies; ACE gene polymorphism in patients with pre-eclampsia.  
Mona Kandil (MBCHB, MSc, PhD,MD) is a professor and head of Clinical Pathology 
department in Alexandria University, and her main research interest is Molecular Chemical 
Pathology.  
Safaa El-Hifni (MBCHB, MSc, PhD, MD) is an emirates professor in Clinical Pathology at 
Alexandria University where she has been head of the department in Alexandria Medical 
Research Institute Teaching hospital till 2001. Her main research interest is analytical 
Chemical Pathology especially Chromatography and mass spectroscopy. 
C Co or rr re es sp po on nd di in ng g   
a ad dd dr re es ss s   
Dr Mohamed Elsammak, Medical Research Institute hospital, 165 El-Horreya Street, 
Department of Chemical Pathology. POB: 21561 Alexandria, EGYPT. Email: 
myelsammak@hotmail.com Int. J. Med. Sci. 2004 1: 181-192  182 
1.  Introduction 
Homocysteine lies at an important metabolic branch point of methionine metabolism, between the 
remethylation and transsulfuration pathways [1]. These lead to the formation of methionine and 
cystathionine, respectively [2,3]. Several enzymes regulate these pathways under normal conditions [4-
6]. Methionine formation is tightly tied to a vitamin B12-dependent enzyme [4,7,8] methionine 
synthase, which uses 5-methyltetrahydrofolate as a carbon donor [6] . This donor is synthesized by the 
methylenetetrahydrofolate reductase (MTHFR) gene from 5,10-methylene-tetrahydrofolate [9,10]. 
Reduction in the activity of these enzymes caused by congenital defects and/or deficiencies in folate 
may affect the normal homocysteine pathway [9, 11]. 
A relationship between hyperhomocystinemia and cardiovascular disease is well established [12-
15]. A thermolabile variant of MTHFR, with reduced specific activity has been described [16]. Frosst et 
al [17] identified that a substitution of cytosine (C) by thymine (T) at nucleotide 677 of the MTHFR 
gene that converts an alanine to a valine residue was responsible for the thermolability of MTHFR. 
Actually, the frequency of the mutated allele was quite high, depending on the ethnic group analyzed 
[18-21]. Some authors suggested that the homozygosity for the MTHFR C677T polymorphism was 
associated with an increased risk of coronary heart disease [9,22] whereas others failed to demonstrate 
this association [23-25]. Furthermore, a recent meta-analysis study pointed at a moderate increase in 
plasma homocysteine and the risk of CVD in patients with MTHFR mutation [26].  
The tHcy level is strongly dependent on the folate and vitamin B12 status of each individual 
[27,11,28]. Plasma tHcy may be increased in cases of severe, folate deficiency [8] and folate 
supplements reduce plasma tHcy levels [29]. The response to folate supplements is affected by the 
number of the 677T alleles in the MTHFR gene, with the strongest response in 677T homozygotes [30]. 
On the other hand, the association between carotid and coronary artery disease is well recognized [31] 
and ultrasonography of the carotid arteries with measurement of the carotid intimal thickness (CIT) had 
been shown to correlate with the severity of atherosclerosis [31].  Some studies showed a strong 
correlation between elevated plasma homocysteine, MTHFR mutation and CIT [32,33] while others 
gave equivocal results [34,35].                                                                                                          
No data are available about the frequency of the MTHFR mutation and its relation to tHcy in the 
Egyptian population. Thus the aim of the present study was to determine  tHcy level and its relationship 
to MTHFR C677T polymorphism in patients with established coronary heart disease, age and sex 
matched elderly subjects and in healthy young controls.                                                                     
2.  Material and methods 
Subjects 
The current study was carried on three groups. A control group
 (n=50) consisted of healthy young 
male volunteers, their age ranged between 35-50 years (Gp1). Another group of healthy elderly subjects 
not complaining of any cardiovascular disease their age ranged between 50-75 years (Gp2). The 
patients group (Gp3) consisted of a total of 50 unrelated male patients with past history of myocardial 
infarction (age ranged between 50-75 years). All patients and controls were living in the same 
geographic area of Northern Egypt (Alexandria), all of them had the same life style (non of them was 
heavy smoker, had excessive alcohol consumption or special dietary habit). The exclusion
 criteria for all 
groups were as follows: vitamins supplementation (e.g. betaine,
 choline, folate, vitamin B6, or vitamin 
B12), the presence of any
 form of cancer, liver disease, primary renal disease or any collagenic diseases.  
All subjects gave informed consent before the study began. Patients who had history of myocardial 
infarction (confirmed by ECG findings and elevated troponin T) were included in the study. All patients 
and controls had a full clinical examination, including history taking, blood pressure measurement and 
carotid ultrasonography for measurement of the carotid artery intimal thickness to assess the degree of 
atherosclerosis [36]. This was done using the ultrasonic machine TOSHIBA core-vision equipped with 
high frequency linear array transducer. The examination was done for the right and left common carotid 
arteries and the mean values of the two sites were used in the analysis. The transducer was positioned 
over the common carotid artery screening it from the origin up to the carotid bifurcation looking for any 
changes, plaque formation with measurement of the vessel thickness. Measurement of the CIT was Int. J. Med. Sci. 2004 1: 181-192  183 
done at the far wall of the vessel 1cm proximal to its bifurcation. Mean CIT was calculated as the 
average of five measurements to each common carotid artery [36]. 
Blood Collection 
All blood samples were collected after an overnight fast (>10 hours)
 by venipuncture into an 
EDTA containing tube. A separated aliquot was kept for DNA extraction. Plasma samples were 
obtained by double centrifugation at room temperature for 15 minutes
 at 2000g. The plasma aliquots 




  Biochemical investigations including blood glucose, cholesterol, triglycerides, high density 
lipoprotein, urea and creatinine were carried out using Kone Lab. auto-analyzer.  Plasma tHcy was 
determined by immunoassay (Abbott Laboratories, North Chicago, IL, U.S.A.). Plasma folate levels 
were measured by radioimmunoassay using a commercial kit (Dualcount Charcoal Boil Assay, 
Diagnostic Products Corporation, Los Angeles, CA). 
MTHFR mutation analysis 
DNA Extraction: 
Genomic DNA was isolated from nucleated blood cells using a phenol chloroform method [37]. 
DNA samples were kept at -80°C till analysed. 
PCR-RFLP analysis 
The C677T MTHFR gene mutation was detected by PCR-RFLP analysis using Hinf I restriction
 
analysis of a 198-bp polymerase chain reaction–amplified
 fragment in the gene for MTHFR, according 
to Frosst et al [17]. Briefly, about 50 to 80 ng DNA samples were amplified in a final volume of 25 µL 
containing 1×PCR buffer with 1.5 mmol/L MgCl2, 2 unit Taq DNA polymerase, 100 µmol/L dNTP, 
and 0.5 µmol/L of each primer (5'-TGAAGGAGAAGGTGTCTGCGGGA-3'  and 5'-
AGGACGGTGCGGTGAGAGTG-3'). PCR was performed in a GeneAmp,  thermocycler (Biorad, 
USA), and the profile consisted of an initial melting
 step of 2 min at 94°C; followed by 35 cycles of 30 
s at
 94°C, 30 s at 61°C, and 30 s at 72°C; and a final
 elongation step of 7 min at 72°C.
  
The restriction enzyme Hinf I (Promega, UK) was used to distinguish the C677T polymorphism, 
and the
 gain of a Hinf I restriction site occurs in the polymorphic allele.
 The wild genotype (677C) has a 
single band representing the
 entire 198-bp fragment, and the heterozygous genotype (677T) results
 in 
three fragments of 198, 175 and 23 bp, while the homozygous for the MTHFR mutation results in 2 
fragments 175 and 23 bp. Finally the products of the Hinf I digestion were electrophoresed on 3% 
agarose gel. 
To ensure quality control, genotyping was performed with blinding
 to case/control status, and 
random samples of cases
 and controls were tested twice by different
 persons, and the results were 
concordant for all masked cases. 
Statistical analysis: 
The distributions of plasma tHcy concentrations
 were positively skewed; therefore, they were 
transformed logarithmically
  to approximate normal distribution, and such data were analysed 
statistically. Statistical analysis of the data analysis was carried out using the ANOVA test. Prevalence 
of alleles and genotype among cases and control subjects were counted and compared with Hardy–
Weinberg predictions [38]. Chi-square
 test (χ 
2, Fisher's
 exact test) was used to test the distribution of 
the different genotypes in the different groups. For correlation studies, Pearson correlation test was 
used. P value of < 0.05 was considered statistically
 significant.
 Statistical analysis was performed using 
SPSS 10 statistical Package. 
3.  Results 
The results of some clinical data and biochemical results of the different groups included in this 
study are shown in table I. Results are expressed as the (range) mean ± SD. As expected there was a 
significant increase in the blood pressure level with age which was especially noted in the patient group Int. J. Med. Sci. 2004 1: 181-192  184 
(age ranged between 50 and 75 years). The mean values of the carotid intimal thickness (CIT) were 
significantly higher in the patients group (Gp3) and the elderly healthy control group (Gp2) compared 
with the healthy young control group (Gp1). As regard the glycemic state, there was a significant 
increase in the blood glucose level both fasting and post-prandial in the patients group (Gp3) compared 
with Gp1 and Gp2. Also total cholesterol and creatinine were significantly higher in the patient group 
compared with the control and Gp2 (P< 0.05).                             
Plasma folate showed no significant difference between the patients group and the other two 
groups. There was poor correlation between the plasma tHcy and folate level.                                                                
Figure 1 shows an agarose gel illustrating the different genotypes of the C667T mutation. The wild 
type CC shows a single band at the 198 base pair (Bp). The heterozygote CT showed two bands, one at 
the 198 and the other at the 175 base pair respectively (the third band of 23 base pairs could not be 
visualized on the agarose gel). The homozygote TT showed a single band at the 175 Bp.  Table II shows 
the frequency of each genotype in the three studied groups and the results of the Chi square testing 
comparing each genotype in the three different groups. There was no significant difference in the 
occurrence of the TT genotype in any of the studied groups (P>0.05). Also the prevalence of the 
different genotypes did not deviate from the Hardy–Weinberg equilibrium for the control group, Gp2 or 
patients group.                                                                                    
As regard the plasma tHcy, the means ± SD of Gp1, GP2 and GP3 were 17.99 ± 9.76, 39.9 ± 20.06 
and 43.8 ± 13.13 µmol/L respectively. There was a significant elevation of plasma tHcy in the patient 
group (Gp3) and healthy elderly (Gp2) compared to the control group (Gp1) (Figure 2).                                                
Plasma tHcy levels were compared in the CC and TT genotypes in the different groups to 
investigate the effect of the mutant allele (T). There was no significant difference regarding the tHcy 
between the CC and TT genotypes in Gp1 or Gp2. The CC genotype had a plasma tHcy of 18.74 ± 
11.26 and 38.55 ± 22.63 µmol/L, while the TT genotype had a plasma tHcy of 12.2 ± 4.58 and 36.25 ± 
8.96 in Gp1 and Gp2 respectively. On the other hand, in the patients group the CC genotype had an 
even significantly higher plasma tHcy when compared with the TT genotype (P<0.05). The CC and the 
TT genotypes had plasma tHcy of 51.09 ± 28.37 and 22.33 ± 6.71 respectively. (Figure 3)                                            
When plasma tHcy was correlated with age, there was a significant positive correlation. The 
correlation coefficient value was 0.564. There was also a significant positive correlation between the 
level of the tHcy and the total cholesterol, urea, creatinine and the fasting and postprandial blood 
glucose.  The correlation was significant at the 0.01 level.                                                             
Figure 4 shows the result of the carotid ultrasonography in a patient with coronary heat disease and 
a young control subject. There was an apparent thickness of the carotid intima in the patient 
ultrasonography when compared with the control. Furthermore, there was a weak positive correlation 
between the CIT and the tHcy level, the correlation coefficient was 0.34. 
4.  Discussion 
The principle findings of this study include the followings: first MTHFR gene mutation does not 
seem to be associated with the occurrence of coronary heart disease or the elevation of plasma tHcy in 
the studied patients. Plasma tHcy was significantly higher in elder patients with cardiovascular 
complications compared with the young control group. There was a significant positive correlation 
between plasma tHcy and age. Also, the high plasma tHcy was associated with the presence of mildly 
elevated serum urea and creatinine and poor glycemic control in the patients group. Moreover, the tHcy 
level correlated positively with the total serum cholesterol.  
In this study, plasma homocysteine in the young control group was higher than the reference 
ranges provided by other studies performed at different ethnic populations [8,14,24]. This might 
represent an ethnic difference in plasma homocysteine and warrants a reference range study in the 
Egyptian population. The significantly higher plasma tHcy in the patients group compared with the 
young control group (Gp1) falls in line with the results of several previous studies which highlighted 
the causal relationship between the occurrence of the coronary heart diseases and the high plasma tHcy 
[14, 39, 40]. This finding might explain the higher degree of CIT in Gp2 and Gp3 compared to Gp1 
(young healthy controls).  It is hypothesized that the high tHcy level induces procoagulative effects that 
result in endothelial damage [41,42] that could precipitate the rupture of an established atherosclerotic 
plaque [25, 41,43]. Int. J. Med. Sci. 2004 1: 181-192  185 
Plasma tHcy although affected by several factors that control the metabolism of homocysteine 
pathway [44, 45] the most important determinant of plasma homocysteine is the folate intake [46,47]. 
Several previous reports illustrated the positive effect of folate intake on the reduction of plasma tHcy 
level and subsequent decrease in the incidence of cardiovascular diseases [46-49]. In the present study 
there was no significant difference between the different groups included in this study regarding the 
folate level. Also, there was no correlation between the plasma tHcy and the folate level. This finding 
although surprising, it is in accordance with the result of Verhoef et al [50] who found no significant 
difference in the plasma folate level between patients with vascular diseases and controls[50]. The lack 
of significant difference regarding the folate level in the studied groups might be explained by the high 
level of fruits and green vegetables in the diet of the Egyptian population in general. However, the lack 
of correlation between the plasma tHcy and the folate could be explained by the presence of mild renal 
impairment in the patients group, as evidenced by the significantly higher level of urea and creatinine in 
the patients group compared with the other two groups. This mild renal impairment might cause a 
resistant hyperhomocysteinaemia [51]despite the high folate intake as discussed below. 
As regard the relationship between tHcy and MTHFR mutation, in this study, we did not find a 
significant correlation between high tHcy levels and MTHFR genotypes in our patients. This finding is 
in keeping with a recent report [52] which found no association between the plasma tHcy and the 
MTHFR mutation, although in a meta-analysis, Klerk et al [53] found that the MTHFR 677TT genotype 
was associated with elevated tHcy level. However, most studies did not show an association between 
the MTHFR mutation and subsequent development of cardiovascular diseases [23,24,54]. Our results 
are in keeping with the results of these studies.  
Since Frosste et al [17] suggested the C667T mutation as a possible reason for the occurrence of 
vascular complications; several groups have evaluated this hypothesis in cardiovascular patients from 
different ethnic groups [19, 21, 55]. 
In the current study there was no significant difference between the patients group and the other 
two groups regarding the distribution of the TT genotype. These results are close to the results of 
previous studies that evaluated the TT genotype distribution in other ethnic populations [51,56, 57]. 
In the current study, when cases were stratified according to expression of the T allele and 
reanalyzed for the plasma tHcy, there was no significant increase in tHcy in the TT genotype 
individuals in the different groups. This finding supports more the lack of association between the 
presence of the T allele and the high tHcy levels in our patients. This could be explained by the 
presence of other factors that control tHcy [58,59] especially plasma folate and vitamin B12[30]. 
Furthermore the presence of other DNA mutations that could affect the homocysteine metabolism (e.g. 
A1298C mutation) [60]. Another reason might be the relatively small number enrolled in our study. 
The current study showed a positive correlation between tHcy and age which is in keeping with 
previous results in different ethnic population [24,60, 62, 63]. This could be explained by the presence 
of other factors that raise plasma tHcy with age, especially the increased deterioration in other organ 
functions. The later was reflected in the present study by the higher incidence of impaired glycemic 
control and hypertension. Both have adverse effect on the renal function. Furthermore, previous reports 
found an elevated tHcy in patients with renal impairment and insulin resistance [64-67]. Another 
possible reason may be the generalized slow down of some biological processes in the body with aging 
including methionine metabolism [61]. 
The current study showed a significantly higher plasma glucose level both fasting and post-
prandial in the patient group and Gp2 compared with the control. This impairment in the glycemic 
control most probably reflects a state of insulin resistance. Elevated homocysteine is associated with 
several cardiovascular disease risk factors including endothelial dysfunction and abnormalities of 
clotting functions, which are also common features of insulin resistance syndrome [65]. Several studies 
have shown that the increase in insulin resistance was paralleled by a concomitant elevation of the 
plasma tHcy [66-68]. Furthermore, it has been demonstrated in rat model that hyperinsulinaemia 
suppresses hepatocyte expression of cystathionine beta-synthase enzyme [69] with subsequent 
development of hyperhomocysteinaemia [69]. 
This study also showed a positive correlation between the urea, and creatinine levels and plasma 
tHcy. The noticed impairment in the renal function is probably a complication of the cardiovascular 
disease itself (e.g. hypertension or heart failure) as patients with primary renal disease were not 
included in this study.  This is in keeping with the results of several authors who reported an association Int. J. Med. Sci. 2004 1: 181-192  186 
between the impairment in renal functions and hyperhomocysteinaemia [70-72]. Moreover, Jager et al 
[73] showed that hyperhomocysteinaemia is an independent determinant of the development of 
microalbuminuria among non-diabetic subjects and hypothesized that; tHcy may play a 
pathophysiological role in the development of microalbuminuria [73]. The hyperhomocysteinaemia in 
patients with renal impairment was attributed to loss of renal homocysteine uptake and metabolism [74] 
which normally accounts for about 70% of daily homocysteine removal from the plasma [74, 75]. Thus 
elimination of a substantial homocysteine metabolizing capacity of normal kidneys could account for 
the presence of this refractory high homocysteine despite the high folate level in the patients group [76]  
In the current study, there was a significantly higher serum cholesterol level in the patient group 
when compared with the other two groups. Also, this high cholesterol correlated positively with the 
tHcy level. This high cholesterol might be attributed to increase in weight gain with age, lack of 
physical activity or improper life style with high intake of fatty foods. However, the association of high 
homocysteine found in the current study and the cholesterol level could be explained by causal 
relationship between plasma tHcy and cholesterol. 
Li H et al [77] demonstrated that high plasma tHcy has a positive effect on the hydroxyl methyl 
glutaryl -CoA synthase enzyme ( the rate limiting enzyme in cholesterol biosynthesis) and hence 
hypercholesterolaemia. Furthermore, they suggested that elevated homocysteine increases the 
cholesterol accumulation in the endothelial cells and suggested the use of statins in patients with 
elevated homocysteine even without hypercholesterolaemia. 
In conclusion this study has shown a positive association between elevated plasma tHcy and age. 
There was no association between the MTHFR mutation and either the presence of coronary heart 
disease or the high plasma tHcy in our patients.  Furthermore, there was a positive correlation between 
the plasma tHcy and impairment of both renal functions and glycemic control.  
However, the relationship between plasma tHcy and other mutations in the MTHFR gene such as 
the A1298C and the degree of insulin resistance in the studied groups remains to be addressed.   
Furthermore, a recent report [67] stressed on the crucial role played by cytokines in the evolution of 
insulin resistance. Could hyperhomocysateineamia be a result of derangement of certain cytokine 
production?  
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Tables and Figures 
Table I.  Some clinical and biochemical data of the different groups included in the study. 
 
(Range) Mean ± SD  Parameter 
Controls (Gp1) (n:50)  Healthy elderly (Gp2) 
(n:50)  Patients (Gp3) (n:50) 
Age (years)  (35-50) 42.76 ± 5.24  (50-75) 59.76 ± 8.45  (50-75) 62.92 ± 7. 1 
SBP (mmHg)  (120 -149)134.6 ± 9.3  (133-178) 154. 6 ±14.78∗ (140-180)162.8  ±10.78∗ 
DBP (mmHg)  (73 -93) 85.44 ± 5.4  (74-94) 89.4 ± 5.43  (88-110) 97.2 ± 6.85∗ 
CIT (mm)  (0.3-0.64) 0.47 ± 0.103   (0.7-1.2) 0.86 ± 0.14∗ (0.7-1.6)1.03  ± 0.26∗ 
FBG (mmol/L)  (4.1-6.1) 5.2 ± 0.58  (4.3-6.9) 5.8 ± 1.27  (4.1-7.7)6.04 ± 1.17∗ 
PPBG (mmol/L)   (4.2-6.5) 5.13 ± 0.57  (4.3-10.3) 6.2 ± 1.83  (4.2-10.8)7.2 ± 2.34∗ 
TC (mmol/L)   (3-5.2) 4.3 ± 0.46  (3.4-6.8) 4.9 ± 1.14  (3.2-7.6) 6.3 ±1.33∗ 
TG (mmol/L)  (0.81-2.0) 1.4 ± 0.37  (0.84-3.2)1.83 ± 0.81  (0.94-3.1)1.93 ± 0.62∗ 
HDL-C (mmol/L)  (0.83-1.45) 1.1 ±0.23 (0.6-1.76)  1.2  ±0.31 (0.83-1.32)1.1± 1.2 
Creatinine (µmol/L) (79.6-109.6)  104  ±10.9 (106-141.4)125.2  ±18.4∗ (79.6-221)136.5  ± 44.4∗ 
tHcy (µmol/L)  (5.1 -36) 17.99 ± 9.76  (13-76) 39.9 ± 20.06∗ (18-95)  43.8± 23.13∗ 
Folate (nmol/L)  (6-37) 29.04 ±9.71 (19-52)  31.52  ±7.51 (7-49)30.52  ±11.51 
Gp: group, SBP: systolic blood pressure, DBP: diastolic blood pressure, CIT: Carotid intimal thickness in 
millimeters, FBG, Fasting blood glucose, PPBG: Post-prandial blood glucose, TC: Total cholesterol, TG: 
triglycerides, HDL-C. High density lipoprotein cholesterol, tHcy: Total homocysteine.  
∗: Significant difference versus the young control group (Gp1). P<.005 was considered significant. 
Table II.  Frequency of the MTHFR genotypes and the result of the Chi square testing in the different 
studied groups. Showing the frequency and the results of the cross tabulation of the T allele and the 
different genotypes in the studied groups. The total number of cases was 50 in each group. There was 
no significant difference regarding the distribution of the CC, CT, TT genotypes in the three studied 
groups (P>0.05). Chi square test (Exact Fisher test) was used. 
Group  Frequency of the different 
MTHFR genotypes 
Group MTHFR  Genotypes 
 
 
Total P  Value 
 CC%  CT%  TT%   CC  CT  TT    
Gp1  56 36 8  Gp1  28 18 4  50  
Gp2  44 48 8  Gp2  22 24 4  50 0.347 
Gp3  44 44 12 Gp3  22 22 6  50 0.230 
    Total  72  64  14  150   
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Figure 1: Different MTHFR genotypes.3% agarose gel electrophoresis showing the different genotypes 
of the MTHFR mutation. DNA samples were amplified using PCR and digested with Hinf1 restriction 
enzyme. The presence of C to T mutation creates a Hinf1 restriction site. Lane 1: 100 base pairs (Bp) 
ladder marker. Lane 2: Negative control (no DNA was added.) Lane 3, 4, 5: Wild type CC genotype. 
Only one band could be seen at approximately the 198 Bp. Lane 6: CT heterozygous genotype. Two 
DNA fragments could be seen. The first at the 198 Bp, while the second at the 175 Bp. Lane 7: TT 
homozygous genotype. Only one band is seen at the approximately the 175 Bp.  
 
Figure 2.  Plasma homocysteine in the studied groups. Bar Chart illustrating the plasma homocysteine  
in the young control group (Gp1, age range 35-50 years) and the Gp2 (elderly control subjects aged 
between 50 and 75 years) and the patients group (Gp3, age range: 50-75 years). The number of subjects 
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Figure 3. The effect of the T allele on the plasma homocysteine in the different studied groups. Bar 
chart illustrating the effect of the T allele on the level of homocysteine in the different groups. Cases 
were stratified according to the genotype into CC (wild type) and TT (mutant homozygous). MTHFR: 
Methylene tetrahydrofolate reductase. ∗ Significant difference versus the TT genotype. P<0.05. 
 
 
Figure 4.  Ultrasonography for the carotid artery in a control subject and a patient with coronary heart 
disease. Carotid ultrasonography for measurement of the carotid artery intimal thickness (CIT) was 
done using the ultrasonic machine equipped with high frequency linear array transducer. The 
examination was done for the right and left common carotid arteries and the mean values of the two 
sites were used in the analysis. There is an apparent increase in the degree of carotid intimal thickness 
in the examined patient (0.9mm) compared with 0.6 mm in the control subject.  
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